Why carry out this study?

Nipocalimab has shown promising efficacy and safety in patients with certain autoimmune diseases (including generalized myasthenia gravis) in the global population.

However, the pharmacokinetics, pharmacodynamics (PD), and safety data are lacking in the Chinese population.

What was learned from this study?

Single administration of nipocalimab showed consistent PD profiles, with no new safety signal in healthy Chinese volunteers.

Our findings support further development of nipocalimab for the treatment of pathogenic immunoglobulin G-mediated diseases in the Chinese population.